LIC
EBS icon

Laurus Investment Counsel’s Emergent Biosolutions EBS Stock Holding History

Laurus Investment Counsel’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,234
Closed -$6.99M – 42
2021
Q1 		$6.99M Sell
75,234
-45,270
-38% -$4.64M 2.69% 17
2020
Q4 		$10.8M Buy
120,504
+510
+0.4% +$46.8K 4.2% 13
2020
Q3 		$12.4M Sell
119,994
-42,375
-26% -$4.57M 6.09% 6
2020
Q2 		$12.8M Buy
162,369
+88,200
+119% +$6.57M 6.88% 4
2020
Q1 		$4.29M Buy
74,169
+47,790
+181% +$2.75M 3.1% 15
2019
Q4 		$1.42M Hold
26,379
– – 0.8% 16
2019
Q3 		$1.38M Buy
+26,379
New +$1.23M 0.94% 17

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurus Investment Counsel's EBS Position: Q2 2021 in Review

Laurus Investment Counsel sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 75,234 shares — an estimated $6.99M sold.

Laurus Investment Counsel first reported a position in EBS in Q3 2019 and held it in 7 quarters. The position peaked at $12.8M in Q2 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Laurus Investment Counsel reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Laurus Investment Counsel sold 75,234 Emergent Biosolutions shares in Q2 2021, an estimated $6.99M.
  • Laurus Investment Counsel first reported a position in Emergent Biosolutions in Q3 2019 and held it in 7 quarters.
  • Laurus Investment Counsel's Emergent Biosolutions position peaked at $12.8M in Q2 2020.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Laurus Investment Counsel's 13F filing for Q2 2021, filed 20 Jul 2021.